Frontiers in immunology · 2025
CHASERR-CHD2 dynamics in T cell quiescence and its modulation by cyclosporine.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Budkina Anna, Zubritskiy Anatoliy, Marakulina Daria, Loguinova Marina Yu, Sergeev Nikita A, Medvedeva Yulia A
Аннотация
BACKGROUND: CHASERR, a conserved long non-coding RNA located upstream of CHD2, transcriptionally represses CHD2 in cis. Both genes are highly expressed in lymphocytes, suggesting roles in immune regulation, though their functions remain undefined.
RESULTS: We identified elevated expression of CHASERR and CHD2 in naïve and regulatory T cells through analysis of single-cell and bulk RNA-seq datasets. Both their promoters are bound by FOXP3, the key regulator of Treg cells, and FOXP1, the key regulator of naïve T cell quiescence. Expression dynamics during early T cell activation revealed that a decline in CHASERR precedes a transient increase in CHD2. Correlation analysis linked CHASERR/CHD2 expression to quiescence-associated genes, suggesting a role in maintaining T cell homeostasis. We predicted and experimentally validated that cyclosporine A, a calcineurin inhibitor and potent immunosuppressant, mitigates the transcriptional changes induced by CHASERR loss, notably reducing elevated CHD2 expression in vitro after CHASERR knockdown.
CONCLUSIONS: Our results position the CHASERR-CHD2 axis as a potential regulator of T cell homeostasis and activation. Furthermore, we propose cyclosporine A as a potential therapeutic strategy for conditions involving CHASERR deficiency.
RESULTS: We identified elevated expression of CHASERR and CHD2 in naïve and regulatory T cells through analysis of single-cell and bulk RNA-seq datasets. Both their promoters are bound by FOXP3, the key regulator of Treg cells, and FOXP1, the key regulator of naïve T cell quiescence. Expression dynamics during early T cell activation revealed that a decline in CHASERR precedes a transient increase in CHD2. Correlation analysis linked CHASERR/CHD2 expression to quiescence-associated genes, suggesting a role in maintaining T cell homeostasis. We predicted and experimentally validated that cyclosporine A, a calcineurin inhibitor and potent immunosuppressant, mitigates the transcriptional changes induced by CHASERR loss, notably reducing elevated CHD2 expression in vitro after CHASERR knockdown.
CONCLUSIONS: Our results position the CHASERR-CHD2 axis as a potential regulator of T cell homeostasis and activation. Furthermore, we propose cyclosporine A as a potential therapeutic strategy for conditions involving CHASERR deficiency.